Efficacy and Safety of Telitacicept in the Successful Treatment of Patients with Purpura Nephritis

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

Abstract Title *

Efficacy and Safety of Telitacicept in the Successful Treatment of Patients with Purpura Nephritis

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

jia fan 1062853462@qq.com Shengjing Hospital of China Medical University Department of Gastroenterology shenyang China *

Co-author 2

ping he doctorhe@126.com Shengjing Hospital of China Medical University Department of Gastroenterology shenyang China -

Co-author 3

Co-author 4

Co-author 5

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

Henoch-Schönlein purpura nephritis (HSPN) is a systemic small-vessel vasculitis characterized by leukocytoclastic vasculitis and deposition of IgA immune complexes. It is the most common systemic vasculitis in childhood. However, the reported incidence might be underestimated due to the asynchrony between the cutaneous and renal manifestations, the wide time span of renal involvement, inconspicuous skin symptoms, and limited reporting. In adults, the incidence of HSPN is not low. Currently, the diagnosis and treatment of HSPN primarily refer to the guidelines for IgA nephropathy.

Methods

This article reports five patients diagnosed with HSPN by renal biopsy in our hospital, who showed suboptimal response or intolerance to side effects from conventional medications like corticosteroids, mycophenolate mofetil, or cyclophosphamide. The treatment regimen was adjusted to include gradually tapered corticosteroids combined with Telitacicept.

Results

During treatment, the patients' proteinuria and hypoalbuminemia progressively improved, eGFR remained stable, and no serious adverse events occurred, indicating a favorable safety profile.

Conclusion

Telitacicept may represent another therapeutic option for HSPN.

Kewords